Nevada Coalition for Psychedelic Medicines

Nevada Coalition for Psychedelic Medicines Saving Lives | Revolutionizing Mental Health The Nevada Coalition for Psychedelic Medicines is dedicated to healing through the use of psychedelic substances.

We strive to increase access to and understanding of these substances as potential therapies for mental health and well-being and to eliminate the stigma and criminalization associated with their use. Through collaboration, advocacy, and education, we aim to improve the health and lives of individuals in our state and nation.

For advocates of psꪗchꫀdeꪶic reform, the question is not only whether research should proceed, but how access can expand...
04/15/2026

For advocates of psꪗchꫀdeꪶic reform, the question is not only whether research should proceed, but how access can expand responsibly while reducing the harms created by prohibition.

House Bill 26-1325, introduced March 6, 2026 by Representatives Jarvis Caldwell and Lisa Feret and Senator Matt Ball, proposes a state-supported i᥇oᧁainꫀ research pilot program within the Colorado Behavioral Health Administration (BHA).

The bill would allow the state to support clinical research into i᥇oᧁainꫀ’s potential for treating substance use disorders, post-traumatic stress disorder, and other mental health conditions.

It would also require participating research sites to create benefit-sharing plans with Indigenous communities historically connected to the medicine.

Those requirements raise broader questions about how i᥇oᧁainꫀ research will develop in the United States, including how the medicine is sourced and how communities connected to its cultural origins are included in the benefits of research and commercialization.

Check out the full article to learn more about:
* What the Bill Would Do
* Why Veterans Are Central to the Proposal
* The Indigenous Benefit-Sharing Requirement
* The Sourcing Question Nobody’s Answering
* What Happens Next
https://psychedelicstoday.com/2026/03/09/colorados-ibogaine-bill-could-be-a-landmark-if-it-respects-the-plants-roots/

Cambridge - one of the world’s leading research universities - has been conspicuously absent from the UK’s psꪗchꫀdeꪶic r...
04/14/2026

Cambridge - one of the world’s leading research universities - has been conspicuously absent from the UK’s psꪗchꫀdeꪶic research landscape. Imperial College London led the field from 2008, launching the first formal Centre for Psꪗchꫀdeꪶic Research in 2019. King’s College London followed with clinical trials from 2017 and opened its Centre for Mental Health Research and Innovation in 2023. Others including Bristol, Exeter and University College London established their own psꪗchꫀdeꪶic research programs. While these institutions built reputations as psꪗchꫀdeꪶic research hubs, Cambridge remained on the sidelines.

All that changed in 2024, when the university secured its Home Office license and established the Cambridge Psꪗchꫀdeꪶic Research Group (CPRG), creating the first legal pathway for psꪗchꫀdeꪶic-assisted treatments in the East of England. The group officially launched in March 2025 with its inaugural research day at Clare College that drew more than 150 attendees. 

Now, one year after its official launch, the CPRG is involved in a number of groundbreaking clinical trials and real-world studies; is building the infrastructure and clinical protocols necessary to administer psꪗchꫀdeꪶic-assisted therapy via the National Health Service (NHS), the country’s publicly funded universal healthcare system; and is looking forward to hosting its second annual Cambridge Psꪗchꫀdeꪶic Research Day in April.

Check out the full article, here:
https://psychedelicalpha.com/news/worth-the-wait-cambridge-adds-its-voice-to-uk-psychedelic-science/

Psꪗchꫀdeꪶic drugs, including LᦓD and magic mushrooms, could help people cope with having a life-threatening illness, and...
04/13/2026

Psꪗchꫀdeꪶic drugs, including LᦓD and magic mushrooms, could help people cope with having a life-threatening illness, and research is already being done on the use of M𝐷M𝐴 for the treatment of people with terminal cancer. Auckland University associate professor David Menkes told RNZ the trials were showing positive signs.

Menkes said the use of a psꪗchꫀdeꪶics for treatment could eventually be an alternative for people considering assisted dying.

“We think this may actually reduce the numbers of people who go ahead and have medically assisted dying, which for many people would be considered a good outcome,” he said.

“We have this law in New Zealand now that people can make that informed choice, right, at the end of life. But if they’re doing that because they just find their situation intolerable and they can be relieved of that burden in some other way, then it’s quite possible that they will elect to do that. And then have, perhaps, a few more months to share with family or to do what they need to feel ready to sign off.”

Check out the full article here:
https://www.rnz.co.nz/news/national/592122/study-shows-benefits-of-psychedelic-drugs-for-people-with-life-threatening-illness

Join Nevada Coalition for Psꪗchꫀdeꪶic Medicines for a special screening of In Waves and War, followed by a live panel di...
04/08/2026

Join Nevada Coalition for Psꪗchꫀdeꪶic Medicines for a special screening of In Waves and War, followed by a live panel discussion exploring trauma, healing, and the evolving conversation around innovative approaches to mental health.

In Waves and War is a powerful documentary following three Navy SEAL veterans navigating the invisible wounds of war. Through deeply personal stories and cutting-edge research, the film illuminates the profound toll of trauma while exploring emerging therapeutic approaches that are reshaping how we understand healing and recovery. The film blends intimate storytelling with a broader look at the mental health crisis facing veterans and others living with unresolved trauma.  

Following the screening, guests are invited to stay for a thoughtful panel discussion featuring voices from neuroscience, veteran leadership, medicine, public policy, and law enforcement advocacy. Together, the panel will explore themes raised in the film, including trauma, resilience, mental health, psychedelic research, and the future of healing-centered policy and care.

THIS EVENT IS FREE AND OPEN TO THE PUBLIC!

RENO EVENT DETAILS:

Date: April 30th
Time: 6:00 PM – 9:00 PM (Doors open at 6 PM, film starts 6:30 PM)
Location: Truckee Meadow Community College
Sierra Building | Room 108
Address: 7000 Dandini Blvd, Reno, NV 89512

With panelists:
Dr. Sarah Henry, Neuropsychologist
Jon Dalton, Retired SEAL
Assemblymember Natha Anderson (District 30)

https://www.zeffy.com/en-US/ticketing/in-waves-and-war-reno-screening

LAS VEGAS EVENT DETAILS:

Date: May 14
Time: 6:00 PM – 9:00 PM (Doors open at 6 PM, film starts 6:30 PM)
Location: College of Southern Nevada – West Charleston Campus
Building K, Room WCK101
Address: 6375 W. Charleston Blvd., Las Vegas, NV 89146

With panelists:
Dustin Hines, PhD, UNLV
Jon Dalton, Retired SEAL
Assemblymember Dr. Rebecca Edgeworth (District 35)

With moderator:
Lt. Diane Goldstein (Ret.)

https://www.zeffy.com/en-US/ticketing/in-waves-and-war-las-vegas-screening

Perhaps the most significant recent development came not from a new bill, but a progress update on an existing program a...
04/08/2026

Perhaps the most significant recent development came not from a new bill, but a progress update on an existing program announced right as March came to a close. On March 31st, Texas Lt. Governor Dan Patrick and House Speaker Dustin Burrows released a joint statement announcing that the state would be moving forward with its $50 million i᥇oᧁainꫀ research program. (Some advocates later said that the state is committing to a full $100 million, even.)

However, unlike what lawmakers had originally envisioned in SB 2308, this progress will be led exclusively by in-state medical research teams as the state’s Health and Human Services Commission says that no drug developer has submitted a suitable proposal.

Elsewhere, the growing trigger law movement continued to gain significant ground in states such as South Dakota, Mississippi, and West Virginia. Meanwhile, Oregon officially signed into law substantive modifications to its flagship ps𝒾𝓁𝑜cy𝒷𝒾𝓃 program, and legislative decisions in Massachusetts signaled a potential preference for regulated access over decriminalization.

Follow the link below for a state-by-state round-up of psꪗchꫀdeꪶics-related bill activity in March 2026.
https://psychedelicalpha.com/news/march-2026-psychedelic-bill-round-up/

Currently, psꪗchꫀdeꪶic therapies are under FDA review and have been lauded by some politicians and advocates for their p...
04/07/2026

Currently, psꪗchꫀdeꪶic therapies are under FDA review and have been lauded by some politicians and advocates for their potential in treating veterans affected by conditions that include post-traumatic stress disorder, depression, substance use disorders, traumatic brain injury, and chronic pain.

If passed, the Office of Novel Therapeutics within the Veterans Health Administration would be established with the following parameters:
* Developing national clinical standards and care models for intensive therapeutic interventions.
* Assessing workforce readiness and national training standards for clinicians and peer support specialists involved in emerging therapeutic interventions.
* Creating a clinical implementation program to evaluate the safety, effectiveness and feasibility of emerging therapies.
* Authorizing VA to designate “Centers of Excellence” to lead research, training and implementation of emerging therapies and share best practices across VA medical centers.
* Establishing a veteran advisory committee composed of veterans, caregivers, academic affiliates and subject matter experts to provide input on patient safety, access and patient-centered care.
* Requiring coordination with federal partners, including FDA, HHS, CMS, DOD and DEA, to support regulatory readiness and reimbursement pathways.
* Requiring annual reporting to Congress on research progress, clinical outcomes, workforce readiness and implementation barriers.

Check out the full article here:
https://www.military.com/daily-news/2026/04/06/major-step-new-law-would-prep-va-fda-approved-psychedelic-treatments.html

Despite overwhelming support for the idea in past years, Thursday marks the first time the House has sent the bill on to...
04/06/2026

Despite overwhelming support for the idea in past years, Thursday marks the first time the House has sent the bill on to the Senate, with a vote of 137 to 11.

While the bill was originally focused on helping veterans, Republican state Rep. Matthew Overcast pushed to expand the bill to also include first responders.

This bill requires the Missouri Department of Mental Health to provide grants totaling $2 million for the research on alternative therapies, subject to lawmakers approving the appropriation.

The state would collaborate on the study with a Missouri university hospital or medical center operated by the U.S. Department of Veterans Affairs in Missouri. The focus of the treatment is on veterans suffering from post-traumatic stress disorder, depression, substance use disorders, or for those who require end-of-life care.

The su***de rate among veterans in Missouri is nearly double the state rate and one of the highest in the country.



Check out the full article here:
https://www.newstribune.com/news/2026/apr/05/missouri-house-passes-bill-to-study-psilocybin-therapy-for-veterans-first-responders/

Katharine Harris, a fellow in Drug Policy at Rice University’s Baker Institute for Public Policy, said in some ways she ...
04/03/2026

Katharine Harris, a fellow in Drug Policy at Rice University’s Baker Institute for Public Policy, said in some ways she was not surprised that the state could not find a private-sector drug company to partner with on i᥇oᧁainꫀ research.

State lawmakers set several requirements that companies had to meet. They needed to propose a feasible plan to develop i᥇oᧁainꫀ and obtain FDA approval, establish a corporate presence in the state, match the $50 million state investment, and agree to allow the state to receive at least 20% of the future sales of the drug.

“That may have been somewhat of a demanding ask in this research area, which is relatively high risk in terms of both the regulatory environment and also the scientific and medical side of it,” Harris said. “I think it’s not all that surprising that they had some difficulty finding an applicant who met the requirements.”

“It is certainly possible that there were very few that could have met this bar, and maybe those that could have didn’t want to, but we need more information to really be able to understand that decision,” Harris said.

Check out the full article here:
https://www.kvue.com/article/news/local/texas/texas-ibogaine-research-program-unable-drug-company-partner/269-164c7307-f6f0-48eb-b3b4-87d1fa5e7460

I᥇oᧁainꫀ and the Bicameral Mind is the definitive guide to the transformational potential of the world’s most complex ps...
04/01/2026

I᥇oᧁainꫀ and the Bicameral Mind is the definitive guide to the transformational potential of the world’s most complex psꪗchꫀdeꪶic medicine. After years of development, the book is published by Park Street Press and is available to pre-order today.

“Jonathan Dickinson has spent years at the intersection of indigenous wisdom, clinical practice, neuroscience, and human struggle. Through his work in Mexico and his engagement with traditional practitioners in Central and West Africa, he offers a perspective few others possess. His writing is not sensationalized. It is measured, observant, and informed by years of listening-to patients, to healers, to scientists, and to families desperate for answers.” Foreward by: Rick Perry; Chairman of Americans for I᥇oᧁainꫀ and Former Governor of Texas

Whether you’re an Ambio alum reflecting on your own journey, a clinician seeking to understand i᥇oᧁainꫀ’s mechanisms, or if you’re considering or preparing for treatment, this book offers both depth and rigor, balancing science and spirituality. I᥇oᧁainꫀ and the Bicameral Mind offers not only a deeper understanding of this medicine and our relationship with it, but a new framework for engaging with the complexity and therapeutic potential of altered states of consciousness.

Ibogaine and the Bicameral Mind releases September 8, 2026, and pre-orders are available now at jonathandickinson.ca
https://shop.jonathandickinson.ca

Americans for I᥇oᧁainꫀ is a 501(c)(3) nonprofit organization advancing science-based education, clinical research, and r...
04/01/2026

Americans for I᥇oᧁainꫀ is a 501(c)(3) nonprofit organization advancing science-based education, clinical research, and responsible medical access to i᥇oᧁainꫀ therapy for addiction and trauma.

They are an organization dedicated to advancing understanding and responsible medical access to i᥇oᧁainꫀ therapy for individuals struggling with addiction, trauma, and co-occurring mental health conditions.

They bring together clinicians, researchers, veterans, first-responders, policymakers, and advocates united by a shared conviction: that every American deserves access to the most promising evidence-based treatments available—including i᥇oᧁainꫀ.

Founded to address the growing disconnect between emerging i᥇oᧁainꫀ research and U.S. regulatory policy, AFI serves as a credible, nonpartisan bridge between the scientific community, Congress, state legislatures, and the public.

To learn more about the great work being done by AFI, check out their website linked below:
https://www.americansforibogaine.org/about/

Under House rules, the measure had to go back to the Finance Committee and then pass again in the full chamber in order ...
03/31/2026

Under House rules, the measure had to go back to the Finance Committee and then pass again in the full chamber in order to advance to the Senate. The committee deemed the bill inexpedient to legislate, and when it got to the floor for the second time on Thursday, members overturned that recommendation and then adopted the major change that only contemplates a potential regulated access model instead, with an advisory board tasked with studying the issue. That dialed-back version ultimately passed.

“The purpose of this act is to study the feasibility of the creation of a carefully monitored and closely supervised setting in which an approved medical provider can treat a carefully chosen patient with appropriate doses of ps𝒾𝓁𝑜cy𝒷𝒾𝓃 which that same provider has produced for a medical intervention,” the bill, HB 1809, says.



Check out the full article here:
https://www.marijuanamoment.net/new-hampshire-house-passes-scaled-back-psilocybin-bill-while-rejecting-measure-to-protect-medical-marijuana-patients-gun-rights/

Address

415 S Beretania St
Honolulu, HI
96813

Website

Alerts

Be the first to know and let us send you an email when Nevada Coalition for Psychedelic Medicines posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to Nevada Coalition for Psychedelic Medicines:

Shortcuts

Share

Share on Facebook Share on Twitter Share on LinkedIn
Share on Pinterest Share on Reddit Share via Email
Share on WhatsApp Share on Instagram Share on Telegram